A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis

(2019) Peter C. Taylor et al.   Arthritis & Rheumatology

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

(2019) Masayoshi Harigai et al.   Modern Rheumatology

Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia‐Pacific region: Post‐hoc analyses of pooled clinical study data

(2019) Eun Bong Lee et al.   International Journal of Rheumatic Diseases

Peficitinib: First Global Approval

(2019) Anthony Markham et al.   DRUGS

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

(2019) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

(2019) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Upadacitinib: First Approval

(2019) Sean Duggan et al.   DRUGS

Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials

(2019) Ying‐Chou Chen et al.   International Journal of Rheumatic Diseases

Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

(2018) Ian C. Scott et al.   DRUG SAFETY

219 Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities

(2018) Bernard Combe et al.   RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Diagnosis and Management of Rheumatoid Arthritis

(2018) Daniel Aletaha et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials

(2017) Yoshiya Tanaka et al.   Modern Rheumatology

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate

(2017) A. J. Kivitz et al.   Arthritis & Rheumatology

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis

(2017) Mark C. Genovese et al.   Arthritis & Rheumatology

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

(2015) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010

(2015) Ayako Nakajima et al.   Modern Rheumatology

Age and Cancer Risk

(2014) Mary C. White et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

(2014) Stanley Cohen et al.   Arthritis & Rheumatology

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis

(2010) M. S. KRATHEN et al.   JOURNAL OF RHEUMATOLOGY

The Japanese experience with biologic therapies for rheumatoid arthritis

(2010) Tsutomu Takeuchi et al.   Nature Reviews Rheumatology

Incidence of malignancy in Japanese patients with rheumatoid arthritis

(2010) Toru Yamada et al.   RHEUMATOLOGY INTERNATIONAL

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

(2009) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM